A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.
Claudia O. Gambrah-Sampaney, MD, Jesse E. Passman, MD, MPH, Andrielle Yost, MPA, and Glen N. Gaulton, PhD
In the past decade, more students than ever entered medical school with the desire, if not the expectation, of participating in meaningful global health experiences.
AMA J Ethics. 2019;21(9):E772-777. doi:
10.1001/amajethics.2019.772.
Haley Moulton, Benjamin Moulton, JD, MPH, Tim Lahey, MD, MMSc, and Glyn Elwyn, MD, PhD, MSc
Shared decision making in research informed consent conversations is complex due to diverse and potentially divergent interests of investigators and patient-subjects.
AMA J Ethics. 2020;22(5):E365-371. doi:
10.1001/amajethics.2020.365.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Drs Katrina Bramstedt and Ana Iltis discuss the development of QoL assessment tools to help patient-subjects considering reconstructive transplantation.